Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.

摘要

In chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) treatment has replaced allogeneic stem cell transplantation (SCT) as first-line strategy while the application of SCT underwent a shift towards patients with high-risk profiles - due to a history of imatinib failure or advanced disease as accelerated (AP) or blast phase (BP). This selection of poor-risk patients is associated with high relapse rates after SCT - as high as 28% in AP and 38% in BP [1].